



Voydeya in Qatar

The MoPH named-patient coordination pathway — indicative 2026

HEMATOLOGY / COMPLEMENT · PNH ADJUNCT (RESIDUAL EVH)

The clinical situation

Voydeya (danicopan) is the first oral Factor D inhibitor, FDA-approved as adjunctive therapy to a C5 inhibitor for adult PNH patients who experience clinically significant extravascular haemolysis (transfusion dependence, ongoing anaemia, or elevated reticulocytes) despite complement inhibition. Manufactured by Alexion (AstraZeneca Rare Disease), it is administered as oral tablets typically three times daily, added to the ongoing C5 inhibitor regimen. Meningococcal and broader encapsulated-organism vaccination per ongoing C5-inhibitor requirements remains gating.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist confirms PNH diagnosis, documents the current C5-inhibitor regimen, and records evidence of residual extravascular haemolysis (transfusion history, reticulocyte count, haemoglobin trend).
- 2 Vaccination review.** Meningococcal and encapsulated-organism vaccination status confirmed per ongoing C5-inhibitor standards.
- 3 MoPH named-patient application.** Physician or hospital pharmacy files dossier: rationale, patient reference, C5-inhibitor co-therapy documentation, oral dosing plan.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed specialty wholesale partner, aligned with the manufacturer's controlled-distribution model.
- 5 Arrival & dosing start.** Controlled-room-temperature shipment; treating physician initiates oral dosing alongside the ongoing C5 inhibitor.

Indicative economics

Reference US cash-pay range: USD 200,000–300,000 annualised adjunctive cost at US list, added to ongoing C5-inhibitor cost (Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

14–21 days from a complete MoPH application to first dispensed supply, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your haematologist and MoPH review, including the adjunctive-therapy documentation block. **Logistics.** Controlled-room-temperature shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Voydeya × Qatar first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/voydeya-qatar.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team